-- Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders ...

That brand is more than just a logo - it’s ... as B2C firms do. Some pharmaceutical brands are even experimenting with influencers, including a recent campaign from Gilead Science.

In a typical case of ownership pass-the-parcel, Cytopia was acquired by Canada’s YM Biosciences and the drug then was in the hands of Gilead and ... to focus on Telix Pharmaceuticals – a ...

In a typical case of ownership pass-the-parcel, Cytopia was acquired by Canada’s YM Biosciences and the drug then was in the hands of Gilead and Sierra Oncology ... s board in 2020 to focus on Telix ...

Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

After a run of court victories in a five-year patent dispute with the U.S. government, Gilead Sciences has agreed to settle with the Department of Justice (DOJ) and the Department of Health and ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

(RTTNews) - Gilead Sciences, Inc. (GILD) and LEO Pharma entered strategic partnership to develop and commercialize LEO Pharma's small molecule oral STAT6 (signal transducer and activator of ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

(Reuters) - Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases. The Danish company will ...